Precise Biopharma Gets CDSCO Panel Nod To Conduct Phase III Trial of Semaglutide Injection
New Delhi: Accepting the bioequivalence study report, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has opined Precise Biopharma to conduct the Phase III clinical trial of Semaglutide (Synthetic Origin) Injection 2 mg/3 ml (0.68 mg/ml, 0.25 mg and 0.5 mg dose), 4 mg/3 ml (1.34 mg/ml,1 mg dose), and 8 mg/3 ml (2.68 mg/ml. 2 mg dose).
This came after the firm presented a bioequivalence study report along with the revised Phase III clinical trial protocol (protocol vide no. CT/2024/33 Version No. 01, dated 24.01.2025) for Type 2 Diabetes Mellitus before the committee.
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults.
GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.